Search
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnThe N-2-cyanoethyl substituent was once believed to be resistant to cleavage, because fenproporex -- once recommended as an obesity treatment for patients with cardiovascular disease -- was originally … Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity.
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma … [L46287] It was fully approved by the EMA in May 2023.[L46596]
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalAs a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.
Mixtures: Mpm Pak, Mpm PakPotassium
go.drugbank.com/drugs/DB14500ApprovedInvestigationalIt was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. … Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms.
Mixtures: Swiss One Multi Vit & Chel Min Tab, Vege Swiss One Multivitamin W Chel Mins TabGallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigationalGallium nitrate is a nitrate salt of [DB14524], a heavy metal that has been used as a diagnostic agent.[A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. … [L47726] Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours.[A260830]
Peripheral Arterial Disease
go.drugbank.com/conditions/DBCOND0000620Synonyms: Peripheral Artery Disease(PAD), Peripheral Artery Disease, PADNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigationalIn addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … [A242412] It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was